An interventional study of Computer-based cognitive rehabilitation (CBCR) and General computer-based cognitive stimulation in Parkinson Disease, Stroke and Cardiac Arrest, sponsored by Bispebjerg Hospital. Active, not recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Bispebjerg Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.
Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 3rd largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2020, is one of 23 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 26th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:
University of Southern Denmark · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18–80
Aarhus University Hospital · Sites in Denmark
Ages 50–80
Hoffmann-La Roche · Sites in Denmark, United States, Australia and 14 more countries
Ages 50–85
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 307 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 75 across the 33 interventional studies, 90 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 50 have an industry lead sponsor. The 10 most frequent:
Bispebjerg Hospital is the lead sponsor of 289 studies on the registry; 29 are open to participants now.
Bispebjerg Hospital has 4 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Parkinson Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06324422University of AarhusExercise as Treatment of Fatigue in Parkinson´s Disease | 2026-12-01 |
| NCT05981261University of AarhusExperimental Pain in Parkinsons | 2027-01-01 |
| NCT07465107Annemette LokkegaardMotor and Cognitive Exercise in Parkinson's Disease. | 2027-02-14 |
| NCT06570824Danish Research Centre for Magnetic ResonancerTMS as an Intervention for Levodopa-induced Dyskinesia | 2027-05-01 |
| NCT07397377Danish Research Centre for Magnetic ResonanceprTMS as an Intervention for Bradykinesia in Parkinson's Disease | 2027-05-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Parkinson Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to generally cognitively stimulating activities on a computer
This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to completing generally cognitively stimulating activities on a computer. A total of 307 patients is expected to be enrolled. All patients will complete a neuropsychological test battery assessing executive functions at inclusion, directly after the eight-week training period and at follow-up three months after the end of the intervention period. Furthermore, all patients will answer questionnaires concerning quality of life and ADL-measures at baseline, after the intervention and at follow-up. All patients will train for a period of 8 weeks, 5 times a week for 60 minutes regardless of their group allocation.
Inclusion Criteria:
Inclusion criteria specific for stroke
Inclusion criteria specific for cardiac arrest
Inclusion criteria specific for Parkinson's disease
Exclusion Criteria:
Exclusion criteria specific for stroke
Exclusion criteria specific for cardiac arrest • None
Exclusion criteria specific for PD
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
154 patients will be allocated to specific computer-based cognitive rehabilitation. This group will train with 10 exercises from the cognitive rehabilitation software 'Scientific Brain training PRO'. These 10 exercises are designed to train various executive functions.
Behavioral: Computer-based cognitive rehabilitation (CBCR)
154 patients will be allocated to general computer-based cognitive stimulation. This group will train with 10 generally mentally stimulating games on a website specifically designed for this trial. These 10 games are chosen because they are believed to have a low load on executive functions but stimulate over-all concentration and visuoperceptual abilities.
Behavioral: General computer-based cognitive stimulation
CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
For this trial we have developed a webpage for general cognitive stimulation, which is designed to provide general computer-based cognitive stimulation.
CABPad Working Memory Test
Test of working memory. The higher score the better (theoretically infinite score)
Time frame: After the end of the intervention (8 weeks after baseline)
CABPad Working Memory Test - 3 months follow-up
Test of working memory. The higher score the better (theoretically infinite score)
Time frame: At follow-up visit 3 months after end of intervention
Minimum Data Set-Home Care- Instrumental Activities of Daily Living (MDS-HC-IADL)
Questionnaire concerning activities of daily living. 0-3 points on an 8-item scale, the fewer points the better.
Time frame: At follow-up visit 3 months after the end of the intervention
Trail Making A
Test of processing speed and visual attention. The lower score the better (theoretically infinite score)
Time frame: Directly after the intervention, eight weeks after inclusion
Trail Making A
Test of processing speed and visual attention. The lower score the better (theoretically infinite score)
Time frame: At follow-up visit 3 months after the end of the intervention
Trail Making B
Test of divided attention, mental flexibility. The lower score the better (theoretically infinite score)
Time frame: Directly after the intervention, eight weeks after inclusion
Trail Making B
Test of divided attention, mental flexibility. The lower score the better (theoretically infinite score)
Time frame: At follow-up visit 3 months after the end of the intervention
SDMT
Symbol Digit Modalities Test: Test of mental speed. The higher score the better (theoretically infinite score)
Time frame: Directly after the intervention, eight weeks after inclusion
SDMT
Symbol Digit Modalities Test: Test of mental speed. The higher score the better (theoretically infinite score)
Time frame: At follow-up visit 3 months after the end of the intervention
Phonological verbal fluency test
Test of verbal phonological fluency. The higher score the better (theoretically infinite score)
Time frame: Directly after the intervention, eight weeks after inclusion
Phonological verbal fluency test
Test of verbal phonological fluency. The higher score the better (theoretically infinite score)
Time frame: At follow-up visit 3 months after the end of the intervention
Categorical verbal fluency test
Test of verbal categorical fluency. The higher score the better (theoretically infinite score)
Time frame: Directly after the intervention, eight weeks after inclusion
Categorical verbal fluency test
Test of verbal categorical fluency. The higher score the better (theoretically infinite score)
Time frame: At follow-up visit 3 months after the end of the intervention
Fear questionnaire
Questionnaire with 24 items concerning fear on a scale from 0 to 8 where 8 indicates a higher degree of avoidance due to fear
Time frame: Directly after the intervention, eight weeks after inclusion
Fear questionnaire
Questionnaire with 24 items concerning fear on a scale from 0 to 8 where 8 indicates a higher degree of avoidance due to fear
Time frame: At follow-up visit 3 months after the end of the intervention
mrs: Modified Rankin Scale
Questionnaire concerning disability on a scale from 0 (no symptoms) to 6 (dead): Higher score indicates more severe disability.
Time frame: Directly after the intervention, eight weeks after inclusion
mrs: Modified Rankin Scale
Questionnaire concerning disability on a scale from 0 (no symptoms) to 6 (dead). Higher score indicates more severe disability.
Time frame: At follow-up visit 3 months after the end of the intervention
IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)
Cognitive decline in the elderly, reported by partner. A scale of 16 items from 1 (much better) to 5 (much worse). Higher score indicates more severe disability.
Time frame: Directly after the intervention, eight weeks after inclusion
IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)
Cognitive decline in the elderly, reported by partner. A scale of 16 items from 1 (much better) to 5 (much worse). Higher score indicates more severe disability.
Time frame: At follow-up visit 3 months after the end of the intervention
EuroQol-5 domain (EQ-5D-5L)
Quality of life scale with 5 domains, each rated from 1-5 indicating slight to severe disability . Higher score indicates more severe disability. Completed by patient and partner
Time frame: Directly after the intervention, eight weeks after inclusion
EuroQol-5 domain (EQ-5D-5L)
Quality of life scale with 5 domains, each rated from 1-5 indicating slight to severe disability. Higher score indicates more severe disability. Completed by patient and partner
Time frame: At follow-up visit 3 months after the end of the intervention
PDQ 39 (Parkinsons Disease Questionnaire: Only in patients with Parkinson Disease)
Quality of Life questionnaire in patients with Parkinson's Disease. A scale with 39 items rated from 1 (never) to 5 (all the time / Can not do at all). Higher score indicates more severe disability.
Time frame: Directly after the intervention, eight weeks after inclusion
PDQ 39 (Parkinsons Disease Questionnaire: Only in patients with Parkinsons Disease)
Quality of Life questionnaire in patients with Parkinson's Disease. A scale with 39 items rated from 1 (never) to 5 (all the time / Can not do at all). Higher score indicates more severe disability.
Time frame: At follow-up visit 3 months after the end of the intervention
Compliance
Monitoring of total time spent training in minutes
Time frame: Directly after the intervention, eight weeks after inclusion
PHQ-9 (Patient health questionnaire 9)
Questionnaire about health of patient with 9 items rated on a 4 point scale from 0 (not at all) to 3 (almost every day). Higher score indicates more severe disability.
Time frame: Directly after the intervention, eight weeks after inclusion
PHQ-9 (Patient health questionnaire 9)
Questionnaire about health of patient with 9 items rated on a 4 point scale from 0 (not at all) to 3 (almost every day). Higher score indicates more severe disability.
Time frame: At follow-up visit 3 months after the end of the intervention
2) visual analogue scale (1-10)
After last session: how much they liked doing the training and if they would recommend the intervention to somebody else in their situation. Higher score indicates they liked the training more.
Time frame: Directly after the intervention, eight weeks after inclusion
Minimum Data Set-Home Care- Instrumental Activities of Daily Living (MDS-HC-IADL)
Questionnaire concerning activities of daily living. 0-3 points on an 8-item scale, the fewer points the better.
Time frame: Directly after the intervention, eight weeks after inclusion
Plan to share: Undecided — This is currently undecided
Started Jun 2020 (actual). Primary completion is estimated for Nov 2026, 77 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 77 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2025 → Nov 2026 and completion Jun 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.